IDH1-MUTATED MALIGNANCIES
Clinical trials for IDH1-MUTATED MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new IDH1-MUTATED MALIGNANCIES trials appear
Sign up with your email to follow new studies for IDH1-MUTATED MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough blood cancers
Disease control Recruiting nowThis phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…
Matched conditions: IDH1-MUTATED MALIGNANCIES
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New study explores ivosidenib dosing for cancer patients with organ issues
Knowledge-focused Recruiting nowThis early-stage study is testing the safety and how the body handles ivosidenib in 30 adults with IDH1-mutated cancers who also have liver or kidney problems. Participants take a daily ivosidenib pill and are monitored closely with blood tests and check-ups. The goal is to learn…
Matched conditions: IDH1-MUTATED MALIGNANCIES
Phase: PHASE1 • Sponsor: Servier Bio-Innovation LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC